- Home
- SPRY vs ELVN Comparison
SPRY vs ELVN Comparison
Compare SPRY & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPRY | ELVN |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 946.0M | 1.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SPRY | ELVN |
|---|---|---|
| Price | $9.86 | $16.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $31.25 | ★ $41.20 |
| AVG Volume (30 Days) | ★ 2.0M | 735.9K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $142,772,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $124.59 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5459.66 | N/A |
| 52 Week Low | $6.66 | $13.30 |
| 52 Week High | $18.90 | $25.37 |
Technical Indicators
Market Signals| Indicator | SPRY | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 52.01 | 36.25 |
| Support Level | $10.02 | $15.71 |
| Resistance Level | $10.71 | $17.58 |
| Average True Range (ATR) | 0.63 | 1.46 |
| MACD | 0.06 | -0.50 |
| Stochastic Oscillator | 34.36 | 16.67 |
Price Performance
Historical ComparisonAbout SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.